PLUVICTO® | Lutetium Lu 177 vipivotide tetraxetan
WEBPLUVICTO can help you be you for longer, giving you the chance for more everyday victories. If you have advanced prostate cancer, you know every day matters. PLUVICTO could give you more time for what's important to you and your loved ones. That's a victory. After hormone therapy and chemotherapy, ask about PLUVICTO.
Lutetium (177Lu) vipivotide tetraxetan - Wikipedia
WEBLutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [3][4] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [4][6]
FDA approves Pluvicto for metastatic castration-resistant ...
WEBThe recommended Pluvicto dose is 7.4 GBq (200 mCi) intravenously every 6 weeks for up to 6 doses, or until disease progression or unacceptable toxicity. View full prescribing information for Pluvicto.
Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto)
WEBLutetium-177 vipivotide tetraxetan PSMA therapy (Pluvicto) is a new theranostic medicine for advanced metastatic prostate cancer. It’s a type of radiation that specifically targets a molecule on the surface of prostate cancer cells called PSMA. This therapy is used with the companion diagnostic gallium-68 gozetotide (Locametz), which is more ...
Novartis Pluvicto™ approved by FDA as first targeted ...
WEBMar 23, 2022 · “Pluvicto is a step forward in the evolution of precision medicine for prostate cancer.” Pluvicto is the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with mCRPC that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle) 1. Pluvicto is expected to be available to ...
Novartis Pluvicto™ shows clinically meaningful and highly ...
WEBOct 23, 2023 · Pluvicto is an intravenous radioligand therapy (RLT) combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177) 9,10. After administration into the bloodstream, Pluvicto binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein 9,10.